Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 2 · 33.3%Low 3 · 50%Moderate 0 · 0%High 0 · 0%

Ursodeoxycholic acid vs placebo or no treatment

Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

Summary of findings: Ursodeoxycholic acid may leads to lower incidence of hepatic veno‐occlusive disease ( compared with placebo or no treatment (low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 0.6 [0.4, 0.88]
4 studies · 612 participants
Low

Ursodeoxycholic acid vs placebo or no treatment

Overall survival ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

Summary of findings: Ursodeoxycholic acid showed no clear difference in overall survival ( compared with placebo or no treatment (low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
HR 0.83 [0.59, 1.18]
3 studies · 474 participants
Low

Ursodeoxycholic acid vs placebo or no treatment

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

Summary of findings: Ursodeoxycholic acid may leads to lower all‐cause mortality at 100 days post‐transplant ( compared with placebo or no treatment (low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 0.7 [0.5, 0.99]
4 studies · 612 participants
Low

Ursodeoxycholic acid vs placebo or no treatment

Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Ursodeoxycholic acid changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 0.27 [0.09, 0.87]
4 studies · 612 participants
Very low

Ursodeoxycholic acid vs placebo or no treatment

Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ursodeoxycholic acid vs placebo or no treatment

Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

It is very uncertain whether summary of findings: Ursodeoxycholic acid changes frequency of adverse events ( compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 0.9 [0.37, 2.22]
4 studies · 612 participants
Very low